Last reviewed · How we verify
NCT02460016
A Study of AK0529 in Infants Hospitalized With RSV
Phase 1 trial testing AK0529 in Respiratory Syncytial Virus Infections in 1 participant. Terminated before completion.
3 November 2015
Quick facts
| Lead sponsor | Shanghai Ark Biopharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 28 August 2015 |
| Primary completion | 3 November 2015 |
| Estimated completion | 3 November 2015 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- AK0529 — full drug profile →
Conditions studied
- Respiratory Syncytial Virus Infections — all drugs for Respiratory Syncytial Virus Infections →
Sponsor
Shanghai Ark Biopharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 1 Month to 24 Months, any sex, with Respiratory Syncytial Virus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single dose of AK0529 in infants hospitalized with respiratory syncytial virus (RSV).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02460016
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AK0529
Trials testing the same drug.
- NCT06942299 — A Study of AK0529 in Adults Patients Hospitalized With RSV Infection · Phase 2 · completed
- NCT04231968 — A Study of AK0529 in Chinese Infants Hospitalized With RSV · Phase 3 · completed
- NCT03699202 — Anti-RSV Study in Chinese Patients (ASCENT) · Phase 2 · unknown
- NCT03400995 — A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529 · Phase 1 · completed
- NCT03322800 — A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Respiratory Syncytial Virus Infections
Currently open trials in the same condition.
- NCT07214571 — A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of · Phase 2 · recruiting
- NCT07220109 — A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 5 · Phase 3 · recruiting
- NCT07239583 — Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · recruiting
- NCT07092865 — A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and th · Phase 2 · recruiting
- NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
Other Shanghai Ark Biopharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06591845 — Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects · Phase 1 · not yet recruiting
- NCT06942299 — A Study of AK0529 in Adults Patients Hospitalized With RSV Infection · Phase 2 · completed
- NCT04926116 — A Study of AK3280 in Chinese Healthy Volunteers · Phase 1 · completed
- NCT04788017 — A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects · Phase 1 · completed
- NCT04231968 — A Study of AK0529 in Chinese Infants Hospitalized With RSV · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02460016 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Ark Biopharmaceutical Co., Ltd.
- Last refreshed: 2 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02460016.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing